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Abstract.  Exposure of bovine aortic or capillary en- 
dothelial cells to basic FGF (bFGF) for 1 h  resulted 
in an approximately sixfold increase in plasminogen 
activator (PA) activity by 18 h that returned nearly 
to basal levels by 36 h. We hypothesized that the de- 
crease in PA activity following bFGF stimulation was 
mediated by transforming growth factor/3 (TGF-/3) 
formed from its inactive precursor. Conditioned me- 
dium collected from endothelial cells 36 h after a  1-h 
exposure to bFGF, but not control medium, inhibited 
basal levels of PA activity when transferred to con- 
fluent monolayers of bovine aortic endothelial cells. 
Antibody to TGF-/3 neutralized the inhibitory activity 
of this conditioned medium, indicating that the me- 
dium contained active TGF-~.  Northern blot analysis 
and quantitation of acid activatable latent TGF-/3 in 
conditioned medium demonstrated that bFGF exposure 
did not increase the amount of transcription or secre- 
tion of latent TGF-/3 by the endothelial cells. Both 
aprotinin, an inhibitor of plasmin, and anti-urokinase 
type PA IgG blocked the generation of active TGF-/~ 
in cultures exposed to bFGE These results demon- 
strated that plasmin generated by uPA activity is re- 
quired for the activation of latent TGF-/3 in endothelial 
cell cultures treated with bFGE Activation of TGF-/3 
by endothelial cells exposed to bFGF appears to limit 
both the degree and duration of PA stimulation. Thus, 
in bFGF-stimulated endothelial cell cultures, PA levels 
are controlled by a negative feedback loop: PA, whose 
expression is stimulated by bFGF, contributes to the 
formation of TGF-fl,  which in turn opposes the effects 
of bFGF by limiting PA synthesis and activity. These 
studies suggest a role for TGF-fl in reversing the inva- 
sive stage of angiogenesis and contributing to the for- 
mation of quiescent capillaries. 
T  rIE importance of complex interactions between pep- 
tide growth factors in mediating cellular physiology is 
becoming increasingly evident. Angiogenesis, a strictly 
regulated process that occurs in a variety of developmental, 
physiological,  and pathological  settings  (Folkman,  1984; 
Furcht,  1986),  can be stimulated  by a number of growth 
factors (Folkman and Klagsburn,  1987). The initial stages 
of angiogenesis  are characterized by local  degradation of 
the basal lamina, followed by migration and proliferation of 
endothelial cells (Ausprunk and Folkman, 1977). The effects 
of angiogenic factors on endothelial  cell proliferation,  mi- 
gration, and protease synthesis have been studied in an effort 
to characterize the contribution of these molecules to neo- 
vascularization.  Two proteins synthesized by almost all cell 
types, including endothelial cells, and believed to contribute 
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to angiogenesis  are basic FGF  (bFGF)  and transforming 
growth factor-B (TGF-B).  ~ 
Basic FGF, an 18-kD peptide,  induces angiogenesis in a 
variety of in vivo assays (Shing et al.,  1985; Folkman and 
Klagsburn,  1987). In vitro, bFGF stimulates endothelial cell 
proliferation  (Gospodarowicz et al., 1985), migration (Sato 
and  Rifkin,  1988), plasminogen  activator  (PA) and  col- 
lagenase synthesis (Moscatelli et al., 1986), invasion into the 
amnion membrane (Mignatti et al., 1989), and formation of 
patent capillaries  in collagen and fibrin gels (Montesano et 
al., 1986). Yet, whereas an increase in protease synthesis is 
necessary for the invasion of endothelial  ceils into a base- 
ment membrane (Mignatti et al., 1986) and subsequent tube 
formation (Montesano et al.,  1986), uncontrolled dissolu- 
tion of matrix interferes with in vitro angiogenesis  (Mon- 
tesano et al.,  1987, 1990). Furthermore, endothelial  ceils 
undergoing normal angiogenesis do not remain indefinitely 
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cell migration stops and new basement membrane is formed. 
Thus, if bFGF contributes to angiogenesis in vivo, a mecha- 
nism must exist for modulating the invasive phenotype that 
it induces. 
TGF-/3 is a 25-kD molecule that is a potent inhibitor of en- 
dothelial cell proliferation, migration,  and protease synthe- 
sis (Heimark et al., 1986; Muller et al., 1987; Saksela et al., 
1987;  Frater-Schroder et al.,  1986). It is secreted constitu- 
tively by endothelial cells as part of a high molecular weight 
complex (180-210 kD) (Flaumenhaft, R., M. Abe, Y. Sato, 
K. Miyazono, C. H. Heldin,  and D. B. Rifldn, manuscript 
submitted for publication)  consisting of mature TGF-/3 as- 
sociated through noncovalent interactions with a 75-kD la- 
tency-associated peptide (Derynck et al.,  1985) that is di- 
sulfide-linked to a 125-190-kD latent TGF-/~ binding protein 
(Miyazono et al.,  1988).  Mature TGF-B must be released 
from this complex to bind to its cell surface receptor and to 
elicit a biological response (Lawrence et al.,  1985; Pircher 
et al.,  1986). Activation of latent TGF-/3 occurs in co-cul- 
tures of endothelial cells and smooth muscle cells (Antonelli- 
Orlidge et ell., 1989; Sato and Rifldn, 1989) and is mediated 
by plasmin cleavage of the aminoterminal propeptide (Lyons 
et al., 1988,  1990; Sato and Rifkin, 1989; Sato et al., 1990). 
TGF-/3 inhibits endothelial cell proliferation, migration, and 
protease synthesis in cell cultures, and it induces tube forma- 
tion when added to endothelial cells grown in three-dimen- 
sional  collagen  gels  (Madri  et al.,  1988;  Merwin  et al., 
1990). In addition, "I'GF-/3 is angiogenic when injected sub- 
cutaneously into newborn mice (Roberts et al.,  1986) or in- 
troduced into the chick chorioallantoic membrane (Yang and 
Moses,  1990). However, since TGF-/~ is a potent chemoat- 
tractant for macrophages and fibroblasts, it might induce an- 
giogenesis indirectly by attracting cells that secrete factors 
capable of initiating  angiogenesis. 
Although TGF-/3 may not act directly on endothelial cells 
during the invasive stage of angiogenesis, it may be involved 
in  resolving  the angiogenic  process.  TGF-/~ increases  the 
production  of the  type  1 plasminogen  activator  inhibitor 
(Laiho et al.,  1986; Lund et al.,  1987; Saksela et al.,  1987) 
and the tissue inhibitor of metalloproteinases  (Edwards et 
al.,  1987; Overall et al.,  1989). This results in the suppres- 
sion of extracellular proteolytic activity and blockade of en- 
dothelial cell invasion (Mignatti et al.,  1989; Pepper et al., 
1990). TGF-/3 has also been shown to stimulate production 
of extracellular  matrix  components  and  the  formation  of 
cell-cell junctions in endothelial cells (Madri et al.,  1989; 
Merwin et al.,  1990; Newton et al.,  1990). If TGF-/~ is in- 
volved in reversing the invasive stage of angiogenesis and 
mediating the formation of new capillaries, it must be con- 
verted from the latent TGF-/~ secreted by endothelial cells to 
its active form. Thus, we have examined the effect of bFGF 
on the capacity of endothelial cells to activate latent TGF-/3. 
We have also tried to determine whether the activation of 
TGF-/3 has a role in regulating the bFGF-stimulated induc- 
tion of PA activity. 
The results demonstrate that active TGF-/3 is generated by 
endothelial cells exposed to bFGF. The generation of mature 
TGF-/3 is preceded by an increase in PA activity and elicits 
a decrease in PA levels at later times. Inhibition of plasmin 
or PA activity prevents the appearance of active TGF-/3 in en- 
dothelial cells exposed to bFGF, showing that bFGF-induced 
PA is required  for the activation of TGF-/3 via the forma- 
tion of plasmin.  The inclusion of neutralizing  antibodies to 
TGF-/3  in bFGF-treated  cultures  blocks the  normally  ob- 
served decrease in PA activity. Thus bFGF activity may be 
controlled by a negative feedback loop in which bFGF stimu- 
lation of PA production causes the activation of latent TGF-/3, 
which,  in turn,  limits  the degree and duration of the PA- 
inducing activity of bFGE On the basis of these findings, a 
model of angiogenesis is presented that involves the coordi- 
nated activities of bFGF and TGF-/3, and that may have im- 
plications  regarding  the extracellular  regulation of growth 
factor activity. 
Materials and Methods 
Reagents 
Aprotinin was purchased from Sigma Chemical Co. (St. Louis, MO). TGF- 
131 and rabbit and chicken anti-TGF-/31 antibody were purchased from R & 
D Systems (Minneapolis, MN). Recombinant human bFGF was a gift from 
Synergen Inc. (Boulder, CO).  Antibodies against bovine urokinase were 
raised in rabbits by injecting the animals with urokinaso purified from cul- 
tures of  bovine kidney epithefial cells (Odakon et al., 1992). IgG was further 
purified from the serum by affinity chromatography on protein G-Sepharose 
according to the manufacturer's procedure (Pharmacia Fine Chemicals, 
Uppsala, Sweden). 
Cells 
Bovine aortic endothelial (BAE) and bovine capillary endothelial cells were 
isolated as previously described (Folkman et al., 1979; Gross et al., 1982) 
and grown in ccMEM (Flow Laboratories, McLean, VA) supplemented with 
5 % calf serum (Flow Laboratories). 
PA Assays 
Confluent cultures of BAE and bovine capillary endothelial cells were tryp- 
sinized and plated in 24- or 96-well plates in c~MEM containing 5 % calf 
serum at a density of 1  ￿  105/cm  2. After a 2-h incubation at 37~  the 
medium was replaced with fresh c~MEM containing 0.1% BSA. After a 12-h 
incubation at 370C, this medium was discarded and replaced with c~MEM 
supplemented  with 0.1% BSA and either bFGF (10 ng/ml) or no bFGE After 
the indicated times, the bFGF-containing medium was removed, and the 
cells were washed twice with PBS. The medium was replaced with fresh 
c~MEM, 0.1% BSA (with or without anti-TGF-/~ IgG in experiments per- 
formed to assess the role of TGF-/~ in bFGF-induced PA stimulation). After 
the indicated time at 370C, the cells were extracted with 0.5 % Triton X-100 
in 0.1 M sodium phosphate, pH 8.1, and assayed for PA activity as described 
(Gross et al., 1982). Briefly, aliquots of  the cell extract were added to a solu- 
tion containing 0.1 M Tris, pH 8.1, 0.025%  BSA (wt/vol), and 8/~g/ml hu- 
man  plasminogen,  and  the  solution  was  incubated  at  370C  on  125I- 
fibrin-coated wells of a plastic multiwell plate. At 1 and 2 h, aliquots were 
removed from the wells, and the amount of l~I-fibrin degradation products 
released was determined in a gamma scintillation counter. PA activity was 
quantitated using a standard curve generated with human urokinase. Results 
are presented in Ploug units. 
PA Assay  for TGF-f3  Activity 
To measure TGF-/~ formation, confluent monolayers of BAE cells grown in 
96-well plates were incubated at 370C in cxMEM, 0.1% BSA for 10 h and 
then incubated overnight with the indicated additions. The amount of TGF-0 
in these samples was determined by comparing the inhibitory activity in 
these conditioned media to inhibition induced by recombinant TGF-81.  To 
quantitate  acid-activatable  latent  TGF-#5 in  the  PA  assay,  conditioned 
medium was acidified to pH 2.0 with 1 N HC1 and neutralized with NaOH 
after a 30-rain incubation at room temperature before incubation with BAE 
monolayers. After a 12-h incubation, the cells were washed twice with PBS, 
extracted in 0.5 % Triton X-100 in 0.1 M Tris-HC1, and assayed for PA activ- 
ity using the lzsI-fibrin assay (Flaumenhaft and Rifkin, 1992). 
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The inhibition of [3H]thymidine incorporation by CC1-64 mink lung ceils 
as an assay for TGF-~ has been previously described (Danielpour et al., 
1989). Briefly, the cells were trypsinized, centrifuged, and resuspended in 
DME containing 0.2% FCS. 350 pl of medium, containing 5  x  104 cells, 
was tmasfened  to a 24-well plate. After I h at 37~  350 pl of  sample media 
was add~ directly to the test cells and allowed to incubate for 22 h. For 
experiments using concentrated conditioned medium, a Centriprep-10 con- 
centration unit was piet/~Red with BSA and samples were concentrated 20- 
fold by centrifu~Oon at 3,000 S. After the incubation of  CCI-64 cells with 
samples, the ceils were washed twice with PBS and further incubated in 250 
/tl of 3H-thymidine (1 pCi/ml) in DME containing 0.2%  FCS for 2 h at 
37~  After this incubation,  the cells  were fixed with  250  #1  of a  3:1 
(vol/vol) solution of metbanol/acefic acid for 1 h, washed twice with 80% 
methanol, incubated with 250/d of a 0.5% trypsin solution for 30 rain at 
37~  and solubilized with an additional 250 #1 of a 5 % solution of SDS. 
The amount of radioactivity  that remained  associated  with  the cells was 
quantitated  with a beta scintillation counter (Beckman Instruments,  Inc., 
Palo  Alto,  CA). 
Wound Assays for BAE Cell Mismtion 
Confluent moaolayers of BAE cells in 35-mm dishes were wounded with 
a razor blade  as previously described  (Sato and Ritkin, 1988). After  wound- 
ins, the ceils  were washed with PBS and incubated with fresh aMEM, 0.I  % 
BSA in the pnutence or absence of aprofinin or medium conditioned by en- 
dothelial cells as described below. After a 28-h incubation, the cells were 
fixed with absolute  methanol  and stained  with Gicmsa.  Cells that  had 
migrated fiom the edge of the wound were counted in successive (seven) 
125-#m increments using a light microscope xl00 with an ocular grid. The 
cell number reported  in Results represents the mean of  at least four different 
fields. 
To prepare conditioned medium for wound assays, subconfluent cultures 
of BAE cells were plated in 24-well plates as described. The cells were in- 
cubated in the presence  or absence of  bFGF (10 ng/ml). After an 18-h incu- 
bation, the cells were washed twice with PBS, and the medium was n,,placed 
with 300 ~d of fresh aMEM, 0.1% BSA containing aprotinln (50 #g/mi), 
TGF-~I O00 pg/ml), or no addition. After a 24-h incubation, conditioned 
medium from these cells was diluted  1:2 with fresh aMEM, 0.1% BSA. 
Results 
TGF-O Acririty in the Conditioned Medium of 
Endothelial Cells Exposed to bFGF 
We had previously demonstrated that monolayers of en- 
dothelial cells exposed to bFGF for 1 h and washed three 
times with PBS to remove soluble bFGF had elevated levels 
Of  PA activity 24 h after exposure (Flaumenhaft  et at., 1989). 
However, when the analysis was extended for an additional 
24 h, the elevation of PA activity was followed by a dramatic 
reduction in PA levels. Fig. I shows the results of such a time 
course experiment in which subconfluent cultures of BAE or 
BCE cells were incubated in the presence or absence of 
bFGF (10 ng/mi) for 1 h. After this incubation, the medium 
was removed and the cell lysates were assayed for PA activity 
using the nsI-fibrin assay. A  1-h exposure to bFGF resulted 
in an increase in PA activity,  followed by a marked decline 
to basal levels after 36 h in both BAE (Fig. 1) and BCE cells 
(data not shown). 
To determine whether a  soluble inhibitor of fibrinolytic 
activity was generated by endothelial cells exposed to bFGF, 
we incubated BAE cells in the presence or absence of bFGF 
(10 ng/ml) for 1 h, washed twice with PBS, and incubated 
at 37~  with fresh medium. At the indicated times, the con- 
ditioned medium was removed from the cells  and  transferred 
to confluent monolayers of  BAE cells in 96-well plates. After 
a  12-h incubation in the presence of conditioned medium, 
the cells were washed twice with PBS and lysed in 0.5 % "IYi- 
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Figure 1.  Reversal of bFGF-mediated stimulation of PA activity in 
bovine aortic endothelial cells. Subconfluent  cultures of BAE cells 
were incubated in aMEM containing bFGF (10 ng/ml) (solid cir- 
cles), or no bFGF (open circles) for 1 h at 37~  The culture medi- 
um was removed, the cells were washed twice with PBS, and the 
medium was replaced with fresh aMEM. After incubation at 37~ 
for the indicated times, the cells were extracted in 0.5% Triton 
X-100. Cell extracts were assayed for PA activity by the t~I-fibrin 
assay. Error bars illustrate the SDs of  duplicate samples from a rep- 
resemative  experiment. This experiment  was performed four times. 
ton X-100. Fig. 2 shows that the conditioned medium from 
bFGF-treated endothelial cells (solid squares) induced a de- 
crease in the basal levels of fibrinolytic activity of test BAE 
cells. The generation of this soluble inhibitor of fibrinolytic 
activity was preceded by a bFGF-induced increase followed 
by a decrease in cell-associated PA production (Fig. 2, solid 
circles). 
TGF-/~ causes an inhibition of fibrinolytic activity in en- 
dothelial cells (Saksela et al., 1987; Pepper et al., 1990). We 
speculated that latent TGF-~ might be converted to TGF-~ 
in endothelial cell cultures exposed to bFGF because (a) 
plasminogen remains associated with the BAE cells follow- 
ins the 2-h preincubation in 5 % serum (Kojima, S., unpub- 
fished observations), (b) bFGF stimulated a several-fold in- 
crease in PA production in the cells, and (c) plasmin can 
convert latent TGF-~ to mature TGF-~ (Lyons et al., 1988, 
1990;  Sato  and Rifkin,  1989;  Sato  et al.,  1990).  Anti- 
TGF-~/1 IgG was used to determine whether the soluble in- 
hibitory activity generated by bFGF-treated endothelial cells 
was TGF-~. BAE cells were incubated for 1 h in the presence 
or absence of bFGF (10 ng/ml), washed twice with PBS, and 
incubated at 37~  with fresh medium for 36 h. These condi- 
tioned media were transferred to confluent BAE cells and in- 
cubated 12 h in the presence or absence of anti-TGF-~ IgG. 
As shown in Fig. 3, 66% of the fibrinolytic inhibitory activ- 
ity of the conditioned medium was blocked by the inclusion 
of  anti-TGF-~l IgG (P < 0.01). Anti-TGF-~I IgG did not have 
a significant effect on the basal levels of PA activity; nonim- 
mune IgG did not affect the inhibitory activity of the condi- 
tioned medium (data not shown). These results have also 
been reproduced using chicken anti-TGF-~l IgG (data not 
shown). 
The presence of TGF-~ in medium conditioned by endo- 
thelial cells exposed to bFGF was also demonstrated by de- 
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Figure 2.  Suppression of basal PA levels in BAE cells by condi- 
tioned medium from bFGF-treated BAE ceils. Subconfluent cul- 
tures of BAE cells were incubated in c~MEM containing bFGF (10 
ng/ml) or no bFGF for 1 h at 37~  The cells were washed twice 
with PBS, and the medium was replaced with fresh aMEM. After 
incubation at 37~  for the indicated times, the medium conditioned 
by these cells was removed, the cells were extracted in 0.5 % Triton 
X-100, and the cell extracts were assayed for PA levels (solid cir- 
cles). The conditioned medium from these cells was transferred to 
confluent monolayers of fresh BAE cells. After 12 h of incubation 
at 37~  these BAE cells were extracted in 0.5% triton X-100 and 
the ceil extracts were assayed for PA activity (solid squares). The 
data are presented as inhibition of PA levels in BAE cells induced 
by conditioned medium from bFGF-treated cultures compared with 
nontreated controls. Error bars illustrate the SDs of  duplicate sam- 
pies from a representative experiment. This experiment was per- 
formed twice. 
termining its effect on the incorporation of pH]thymidine 
into CC1-64 mink lung cells 03anielpour et al., 1989). TGF-B 
inhibits DNA synthesis in CC1-64 cells (Tucker et al., 1984). 
Concentrated conditioned medium from bFGF-treated BAE 
cells reduced the incorporation of [3H]thymidine into CC1- 
64 cells by ~80% of the level of incorporation observed in 
CC1-64 cells exposed to concentrated control conditioned 
medium (data not shown). The inclusion of  anti-TGF-N IgG 
reversed the inhibition of pH]thymidine incorporation elic- 
Red by conditioned medium from bFGF-treated BAE cells, 
whereas  nonimmune  IgG  did  not.  The  concentration of 
TGF-B generated by BAE cells exposed to bFGF was ,~10- 
20 pg/ml as determined by the PA and pH]thymidine incor- 
poration assays. This value is in agreement with what has 
been detected previously in coculture systems (Sate et al., 
1990). 
Mechanism of TGF-~ Generation in Endothelial Cells 
Exposed to bFGF 
The formation of TGF-B by endothelial cells exposed to 
bFGF could be due to a  bFGF-stimulated increase in the 
secretion of latent TGF-B. To test this possibility, BAE cells 
were  incubated in the presence or absence of bFGF  (10 
ng/ml) for 1 h,  washed twice with PBS, and incubated at 
37~  At the indicated times, the conditioned medium was 
removed and acid-activated as described in Materials and 
Methods. A  1:500 dilution of the acid-treated conditioned 
medium was transferred to confluent monolayers of BAE 
cells and assayed for the ability to suppress the basal level 
of PA activity. The amount of acid-activatable inhibitory ac- 
tivity in the conditioned medium of endothelial cells did not 
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Figure 3. Anti-TGF-~51 IgG partially reverses the PA suppressive 
activity in the conditioned medium of bFGF-treated BAE cells. 
Subconfluent cultures of  BAE ceils were incubated in c~MEM con- 
taining bFGF (10 ng/ml) or no bFGF for 1 h at 37~  The culture 
medium was removed, the cells were washed twice with PBS, and 
the medium was replaced with fresh aMEM. After incubation at 
37~  for 36 h, conditioned medium with or without anti-TGF-/~l 
IgO (100 ~,g/ml) was transferred to confluent monolayers of BAE 
cells. After 12 h of incubation at 37~  the BAE cells were lysed 
in 0.5% Triton X-100 and the cell extracts were assayed for PA ac- 
tivity. (1) Control conditioned medium. (2) Conditioned medium 
from ceils exposed to bFGF for 1 h. (3) Conditioned medium from 
cells exposed to bFGF for 1 h and assayed in the presence of anti- 
TGF-/31 IgG. Error bars illustrate the SDs of duplicate samples 
from a representative experiment. This experiment was performed 
three times. 
not  shown).  The  acid-activatable  inhibitory  activity  was 
blocked by anti-TGF-~l  IgG.  Northern analysis was per- 
formed to  determine  the  levels  of TGF-81  and  TGF-t32 
mRNA  synthesized by bFGF-stimulated BAE cells com- 
pared to untreated control cells. TGF-/31 and TGF-/32 mRNA 
levels were similar in BAE cells exposed to bFGF for 1 h and 
untreated controls when assayed 30 h after bFGF treatment 
(data not shown).  Thus, the generation of TGF-/5 by en- 
dothelial cells exposed to bFGF did not result from a bFGF- 
stimulated increase in the transcription of TGF-B mRNA or 
the secretion of latent TGF-B. 
TGF-B is secreted from endothelial cells as a high molecu- 
lar weight latent complex from which it must be released to 
elicit its biological activity (Lawrence et al.,  1985; Pitcher 
et al.,  1985; Sato et al.,  1990; Flaumenhaft, R., M. Abe, 
Y.  Sato,  K.  Miyazono, C.  H.  Heldin, and D.  B.  Rifkin, 
manuscript submitted for publication). Active TGF-B can be 
released from this latent complex by plasmin cleavage of the 
latency associated peptide of the TGF-/3 molecule (Lyons et 
al.,  1988,  1990; Sate and Rifkin, 1989; Sate et al.,  1990). 
Basic FGF stimulates PA expression in endothelial cells and 
the increase in PA production precedes the generation of ac- 
tive TGF,-B (Fig. 2). To determine whether the generation of 
active TGF-B by endothelial cells exposed to bFGF was 
mediated by plasmin formed by the action of PA on plas- 
minogen, we characterized the effect of the plasmin inhibi- 
tor,  apmtinin,  on the bFGF-induced generation of active 
TGF-f3. The PA assay could not be used for these experiments 
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Figure 4. Aprotinin inhibits the generation of TGF-~ by bFGF-stim- 
ulated BAE cells.  Subconfluent cultures of BAE cells were incu- 
bated in ctMEM with or without bFGF (10 ng/ml) for 18 h at 37~ 
Cells exposed to medium containing no bFGF were washed twice 
with PBS and incubated for 6 h with fresh aMEM (control). Ceils 
exposed to medium containing bFGF were washed twice with PBS 
and incubated for 6 h with either fresh c~MEM containing no addi- 
tion (bFGF), rTGF-#I (300 pg/ml; bFGF then rTGF-#I), or apro- 
tinin (50/~g/ml;  bFGF then aprotinin).  The conditioned medium 
was transferred to monolayers of BAE cells that had been wounded, 
as described  in Materials  and Methods.  As a control,  wounded 
monolayers  were incubated  with  fresh  c~MEM in  the  presence 
(aprotinin) or absence (no addition) of aprotinin (50/~g/ml).  The 
figure illustrates the average and SD of the number of cells per feld 
from a representative experiment. Four fields were counted in each 
sample, and the total number of cells that migrated in the control 
was 105. This experiment was performed  three times. 
since aprotinin would interfere with the assay. The migration 
of endothelial cells into a denuded area of a wounded mono- 
layer of cells is inhibited by TGF-/~ (Heimark et al.,  1986; 
Sato and Rifkin, 1989) and is not affected by aprotinin (Sato 
and Rifldn,  1989). Therefore, the inhibition of migration of 
BAE cells was used to assay TGF-# in medium conditioned 
by cells exposed to bFGF in the presence of aprotinin. 
BAE ceils were incubated in the presence or absence of 
bFGF for 18 h, washed twice with PBS, and incubated with 
medium containing aprotinin,  recombinant TGF-~I, or no 
addition. After a 6-h incubation, the medium conditioned by 
these cells was transferred to wounded monolayers of BAE 
cells.  Nonconditioned  medium  with  or  without  aprotinin 
was used as a  control.  After an overnight incubation,  the 
number of cells that had moved from the edge of the wound 
was determined. Neither aprotinin alone (Fig. 4, aprotinin) 
nor the conditioned medium of untreated cells (Fig. 4, con- 
trol) affected BAE cell migration. In contrast, conditioned 
medium of cells exposed to bFGF inhibited the migration of 
BAE ceils (Fig. 4, bFGF) to a level similar to that achieved 
with medium containing recombinant TGF-/~I (Fig. 4, bFGF 
then rTGF-#I).  However, the medium conditioned by cells 
exposed to bFGF in the presence of aprotinin did not have 
an inhibitory effect on BAE cell migration (P <  0.001) (Fig. 
4, bFGF and aprotinin).  Aprotinin does not interfere with 
the activity of flGF-/~I (Sato and Rifldn,  1989).  Thus, the 
presence of the plasmin inhibitor blocked the generation of 
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Figure 5. Effect of anti-uPA IgG on the generation of'l'GF-/~ by cells 
exposed to bFGE Subeonfluent cultures of BAE cells were incu- 
bated in ,~MEM with or without bFGF (10 ng/ml) for t h at 37~ 
The cells were washed twice with PBS, and the medium was re- 
placed with fresh c~MEM with or without anti-uPA IgG (200 Izg/ 
ml).  After further incubation  for 36 h, conditioned medium was 
transferred onto CCI-64 ceils, incubated for 22 h in the presence or 
absence of anti-TGF-B  1 IgG (I00 #g/ml), and assayed for 3H-thy- 
midine incorporation  as described  in Materials  and Methods.  (1) 
Control conditioned medium. (2) Conditioned medium from cells 
exposed to bFGF for 1 h. (3) Conditioned medium from cells ex- 
posed to bFGF for 1 h and assayed in the presence of anti-TGF-#l 
IgG. (4) Conditioned medium from cells incubated for 36 h in the 
presence of anti-uPA IgG. (5) Conditioned medium from cells ex- 
posed to bFGF for 1 h and incubated for 36 h in the presence of 
anti-uPA IgG. Error bars represent the SD of three experiments per- 
formed in duplicate. 
the  conditioned  medium  of endothelial  cells  exposed  to 
bFGF  derives  from  the  activation  of  latent  TGF-/~  by 
plasmin. 
The activation of latent TGF-13 by plasmin is consistent 
with the observation that a four to eightfold increase in cell- 
associated PA activity precedes the generation of TGF-~/in 
endothelial  cells  exposed  to  bFGF  (Fig.  2).  The  PA  as- 
sociated with these BAE ceils has previously been shown to 
be uPA  (Saksela et al.,  1987;  Saksela and Rifkin,  1990). 
Therefore, experiments were performed using anti-bovine 
uPA IgG to determine whether uPA is necessary for the acti- 
vation of latent TGF-~ (Fig. 5). In these experiments, cells 
were exposed to bFGF for 1 h, washed twice with PBS, and 
incubated in the presence or absence of anti-uPA IgG. After 
a  36-h incubation,  the medium conditioned by these cells 
was tested for the presence of TGF-/3 using the CC1-64 mink 
lung cell  [3H]thymidine incorporation assay.  As  shown in 
Fig. 5, the presence of anti-uPA IgG in the medium blocks 
the  generation  of TGF-/~  in  BAE  cells  exposed to  bFGF 
(P <  .02) (Fig. 5, column 5 vs. column 2). The anti-uPA IgG 
by itself did not suppress (3H]thymidine incorporation (Fig. 
5, column 4).  The fairly large amount of IgG required for 
this effect is consistent with earlier experiments demonstrat- 
ing that the titer of the antibody is low (Saksela and Rifldn, 
1990; Odekon et al., 1992). This result was confirmed using 
the cell migration assay to detect TGF-/3 generated by cells 
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Figure 6. Effect  of  anfi-TGF-/31 IgG on the PA activity of  BAE cells 
exposed to bFGF for 1 h. Subcontinent cultures of BAE cells were 
incubated in aMEM with or without bFGF (10 ng/ml) for 1 h at 
37~  The cells were washed twice with PBS, and the medium was 
replaced with fresh aMEM with or without anti-TGF-/~l IgG (100 
~g/ml). After further incubation at 37~  for 18 h, the cells were 
lysed in 0.5 % Triton X-100 and the cell extracts were assayed for 
PA activity. (1) No addition. (2) Cells exposed to bFGF 1 h and 
incubated in c~MEM  containing no additions for 18 h. (3) Cells in- 
cubated for 18 h in the presence of anti-TGF-/~l IgG. (4) Cells ex- 
posed to bFGF 1 h and incubated in ,~MEM containins anti-TGF- 
~1 IgG for 18 h. Error bars illustrate the SDs of duplicate samples 
from a representative experiment. This experiment was performed 
four times. 
exposed to bFGF and subsequently incubated in the presence 
or absence of anti-uPA IgG (data not shown). Thus, activa- 
tion of latent TGF-/~ by endothelial cells exposed to bFGF 
requires uPA-mediated generation of plasmin. 
Consequences of the bFGF-Induced 
Act/vat/on of TGF-{3 on the PA Activity 
of  Endothelial Cells 
TGF-/~ opposes  the PA-inducing  activity of bFGF in en- 
dothelial cells (Saksela et al., 1987).  To determine whether 
mature TGF-/3 generated by plasmin-mediated activation of 
latent TGF-/3 affects the magnitude of the bFGF-induced 
stimulation of PA activity as well as the subsequent decline 
(Figs. 1 and 2), endothelial cells were incubated in the pres- 
ence or absence of bFGF (10 ng/ml) for 1 h, washed twice 
with PBS, and incubated at 37~  for 18 h in the presence or 
absence of  anti-TGF-/31 IgG (100/~g/ml).  Figure 6 shows that 
the PA activity of endothelial cells exposed to bFGF for 1 h 
and incubated in serum-free medium for 18 h increased four- 
fold relative to untreated cells. Endothelial cells exposed to 
bFGF for 1 h and incubated in serum-free medium contain- 
ing anti-TGF-/31 IgG showed an eightfold increase in PA ac- 
tivity relative to control cells not exposed to bFGF. Anti- 
TGF-/~I IgG had no effect on the PA production of untreated 
cells. This result showed that the stimulation by bFGF elicits 
the activation of latent TGF-/3, which, in turn, reduces the 
stimulatory effect of bFGF. In a second experiment analyz- 
ing PA activity at 48 h, PA activity in BAE cells exposed 
to bFGF for 1 h and incubated in serum-free medium de- 
creased to basal levels, whereas PA activity in endothelial 
cells treated for 1 h with bFGF then incubated in medium 
containing anti-TGF-/3 IgG remained two- to three-fold above 
basal levels (data not shown). Thus, endogenous activation 
of latent TGF-B limits both the degree and duration of bFGF 
stimulation. 
Discussion 
The initiation of angiogenesis requires both basement mem- 
brane degradation resulting from increased endothelial cell 
proteolytic activity and  invasion owing  to  enhanced en- 
dothelial cell motility (Ausprunk and Folkman, 1977).  The 
observation that bFGF is a potent inducer of proliferation, 
migration,  and protease  synthesis in cultured endothelial 
cells (Gospodarowicz et al.,  1985;  Moscatelli et al.,  1986; 
Sato and Rifkin, 1988) is consistent with the role of bFGF 
as an initiator of angiogenesis (Shing et al., 1985; Foikman 
and Klagsbrun, 1987). Yet, the mechanism by which the in- 
ductive effects of bFGF on endothelial cells are reversed to 
elicit the formation of mature capillaries is unclear. Because 
capillary formation requires a diminution of proteolysis and 
cell movement and the deposition of new basement mem- 
branes and formation of  junctional complexes between cells, 
it is unlikely that bFGF alone mediates this process. 
Several  observations  suggest  that  TGF-/~ might act  in 
reversing the invasive stages of angiogenesis and contribute 
to the formation of new capillaries. (a) TGF-B inhibits en- 
dothelial cell migration, fibrinolytic activity, proliferation, 
and invasiveness (Heimark et al., 1986; Muller et al., 1987; 
Saksela et al., 1987; Frater-Schroder et al., 1986; Mignatti 
et al.,  1989;  Pepper et al.,  1990).  (b)  Synthesis of ECM 
components, such as fibronectin and heparan sulfate proteo- 
glycans, in endothelial cells is stimulated by TGF-B (Madri 
et al.,  1989;  Newton et al.,  1990).  (c) TGF-B induces the 
formation of capillaries  by endothelial cells  interspersed 
in a  three-dimensional collagen gel (Madri et al.,  1988). 
(d) Capillary formation is associated with TGF-B-mediated 
changes in ECM  organization and formation of cell-cell 
junctions (Merwin et al.,  1990). 
The data presented in this paper demonstrate that active 
TGF-/3 is formed in subconfluent endothelial cell cultures in 
response to bFGE This result was suggested by the observa- 
tion that after a brief exposure to bFGF the initial increase 
in PA production in endothelial cells was reversed and de- 
creased dramatically at subsequent time points (Fig. 1). The 
factor responsible for eliciting the decrease in PA production 
also elicited a decrease in PA production when transferred 
to fresh endothelial cells (Fig. 2). Three different assays- 
inhibition of PA activity in BAE cells (Fig. 3), the inhibition 
of 3H-incorporation into mink lung cells (data not shown), 
and the inhibition of BAE migration (Fig. 4)-were used to 
demonstrate the presence of active TGF-/3 in the conditioned 
medium ofbFGF-treated cells. The identity of the active fac- 
tor was confirmed by the fact that activity in these assays was 
neutralized by anti-TGF-B1 IgG. TGF-/~ was also generated 
by confluent monolayers of BAE cells treated with bFGF 
(data  not  shown).  In  addition,  both  subconfluent  and 
confluent capillary endothelial cells produced TGF-~ after 
exposure to bFGF (data not shown). Thus, the temporally 
coordinated activation of latent TGF-/~ opposes the stimula- 
tion of PA induced by bFGF and provides a mechanism by 
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tions suggest that "I'GF-/5  may directly contribute to the final 
stages of angiogenesis by antagonizing factors that initiate 
the process. The coordinated activities of bFGF and TGF-/~ 
in mediating PA production in vitro resembles the sequence 
of morphologic events described during angiogenesis in vivo 
(Ausprunck and Folkman, 1977).  However, the time course 
of the in vitro effects illustrated here differs from the in vivo 
process, perhaps because of the continuous exposure of cells 
to bFGF in vivo. 
The mechanism by which TGF-/3 is  released  from the 
latency-associated peptide has not been fully characterized 
but is assumed to be an important step in the regulation of 
the extracellular activity of TGF-/3. The demonstration that 
the PA system is involved in the activation of latent TGF-/3 
by BAE cells (Figs. 4 and 5) and BCE cells (data not shown) 
exposed to bFGF is consistent with previous observations 
that plasmin can elicit the activation of TGF-/3 (Lyons et al., 
1988, 1990).  For example, PA and plasmin have been deter- 
mined to be necessary for the activation of latent TGF-/5 that 
occurs  when endothelial cells are  cultured together with 
smooth muscle cells (Sato and Rifldn,  1989;  Sato et al., 
1990).  However, the activation of latent TGF-~ that occurs 
in these heterotypic cultures is not preceded by an increase 
in PA and requires several other molecules, such as man- 
nose-6-phosphate receptor (Dennis and Rifkin, 1991) and la- 
tent TGF-~-binding protein (Flaumenhaft, R., M. Abe, Y. 
Sato, K. Miyazono, C. H. Heldin, and D. B. Rifldn, submit- 
ted for publication). In contrast, activation of latent TGF-13 
by BAE cells exposed to bFGF occurs only after PA and plas- 
rain levels are increased several-fold (Fig. 2). Yet, high PA 
activity itself does not necessarily elicit the activation of la- 
tent TGF-/5, as demonstrated by the fact that HT1080 cells 
produce more PA than bFGF-stimulated BAE cells but do 
not activate latent TGF43  (Y.  Sato,  unpublished observa- 
tions). These observations suggest that the activation of la- 
tent TGF-/3 by bFGF-treated BAE cells requires PA but may 
not occur exclusively as a result of increased PA. 
The proposed function of TGF-/3 in reversing the invasive 
stage of angiogenesis and contributing directly to the forma- 
tion of  new capillaries is consistent with observations regard- 
ing the activity of  TGF-/5 in other systems. In the skeletal sys- 
tem,  for  example,  the  activation  of bone-derived  latent 
"I'GF-/3 by osteoclasts (Oreffo et al., 1989) is thought to pro- 
mote the expansion and matrix production of the osteoblast 
population (Centrella et al.,  1987; Robey et al.,  1987) and 
inhibit  the  generation  of new  osteoclasts  (Chenu  et  al., 
1988). Thus, the activation of latent TGF-~ may play an im- 
portant role in bone remodeling, linking bone resorption to 
the formation of new bone (Bonewald and Mundy, 1990). 
Monocytes exposed to interleukin-2, tumor necrosis factor, 
or -r-interferon have been shown to activate latent TGF-/~ 
(Lucas et al., 1990, 1991; Twardzik et al., 1990).  TGF-~, in 
turn, inhibits the proliferation and cytotoxic activity of the 
activated cell (Espevik et al.,  1988;  Kuppner et al.,  1988; 
Tsunawaki et al., 1988; Lucas et al., 1990, 1991). Thus, sev- 
eral cell types have been shown to release TGF-/~ from its 
precursor when activated. The generation of TGF-/~ in these 
circumstances serves to reverse the activities of  the activated 
cells and to promote a quiescent state. In this manner, the 
activation of latent TGF-/~ may be a means by which homeo- 
stasis is regained following the initiation of  many physiologi- 
cal processes. 
bFGF  Plasminogen  Plasmin  3)  PAI-I 
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Figure 7. Regulation of PA activity by the bFGF-induced activation 
of latent I-GF-~. Exposure of cells to bFGF (/) results in an in- 
crease in PA expression (2). The increase in PA generates increased 
levels of plasmin (3),  which mediates the activation of constitu- 
tively secreted latent TGF-8 (4).  The activation of latent 'rGF-~ 
results (5) in decreased PA activity through increased synthesis of 
type 1 plasminogen activator inhibitor (6a) as weLl as decreased 
transcription of the urokinase type PA gene (6/7). The subsequent 
decrease in plasmin generation (7) results in inhibition of latent 
TGF-/3 activation. 
Our data suggest a mechanism for the extracellular regula- 
tion ofbFGF activity because PA-mediated TGF-~ activation 
may regulate bFGF activity in any cell type that secretes la- 
tent TGF-13 and demonstrates increased PA levels in response 
to bFGF. Fig. 7 shows a schematic model of how the bFGF- 
induced activation of TGF-13 may regulate PA activity in cells 
that demonstrate increased PA levels in response to bFGF. 
Exposure of  cells to bFGF (/) results in a several-fold increase 
in PA activity (2).  The increase in PA generates increased 
levels of plasmin (3), which contributes to the activation of 
constitutively secreted latent TGF-/3 (4). The activation of  la- 
tent TGF-fl results (5) in decreased PA activity most likely 
by eliciting increased synthesis of PAL1 (6a). TGF-~ might 
also decrease uPA mRNA levels as previously demonstrated 
in calf  pulmonary artery endothelial cells (6b) (Pepper et al., 
1990).  (In BCE cells, Pepper et al. have shown that TGF-~ 
causes an increase in both PAl-1 and uPA transcription but 
the net proteolytic balance is decreased because PAl-1 pro- 
duction is so high.) The subsequent decrease in plasmin 
generation (7)  results in inhibition of latent TGF-~ activa- 
tion. Thus, the activation of latent TGF-~ regulates the de- 
gree of PA stimulation induced by bFGE In this manner, the 
activation of TGF-13 contributes to a negative feedback loop 
in which the stimulation of PA activity by bFGF leads to the 
activation of latent "I'GF-~ and inhibition of PA synthesis and 
activity. This model may represent a general mechanism for 
the control of extracellular proteolytic activity in a variety 
of cell types because bFGF and TGF-/3 are produced by 
many cells. 
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